Lab Med Online.  2017 Jul;7(3):141-146. 10.3343/lmo.2017.7.3.141.

The Clinical Utility of the Autoimmune Target Test for Neurologic Disease

• Kim SH
• Jearn LH
• Kim TY

• KMID: 2383093
• DOI: http://doi.org/10.3343/lmo.2017.7.3.141

Abstract

BACKGROUND
Many studies have reported the association between several anti-neuronal antibodies and neurologic diseases. However, there is no useful autoantibody screening test for neurologic diseases unlike the antinuclear antibody test for rheumatologic diseases. Hence, we investigated the clinical utility of the autoimmune target (AIT) test as screening test for autoantibodies in neurologic diseases.
METHODS
We retrospectively analyzed the results of the AIT test for 375 serum samples of patients diagnosed with several neurologic diseases such as motor neuron disease (MND), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), encephalopathy (EC), polyneuropathy (PN), cerebral ischemic attack, encephalitis, myelitis, epilepsy, and stroke.
RESULTS
The overall positive rate of the AIT test in aforementioned diseases was 77.9%. The positive rates for MND, ALS, PD, EC, PN, and the others were 81.3%, 83.9%, 84.8%, 59.3%, 73%, and 75%, respectively.
CONCLUSIONS
Our results indicate high positive rates in the AIT test. We believe that the AIT test has potential application for autoantibody screening in the neurologic diseases. We look forward to last as the study about relations between the results of the AIT test and the specific antibodies for neurologic diseases.

Keyword

Neurologic disease; Autoantibody; Autoimmune target test

MeSH Terms

Amyotrophic Lateral Sclerosis
Antibodies
Antibodies, Antinuclear
Autoantibodies
Brain Diseases
Encephalitis
Epilepsy
Humans
Mass Screening
Motor Neuron Disease
Myelitis
Parkinson Disease
Polyneuropathies
Retrospective Studies
Stroke
Antibodies
Antibodies, Antinuclear
Autoantibodies

Reference

1. Willison HJ, Gilhus NE, Graus F, Jacobs BC, Liblau R, Vedeler C, et al. European handbook of neurological management. 2nd ed. Chichester: BLACKWELL;2010. p. 75–80.

2. Lee R, Buckley C, Irani SR, Vincent A. Autoantibody testing in encephalopathies. Pract Neurol. 2012; 12:4–13.

3. Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014; 76:82–94.

4. Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol. 2006; 9:336–340.

5. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med. 1999; 5:170–175.

6. Willison HJ, O'Hanlon G, Paterson G, O'Leary CP, Veitch J, Wilson G, et al. Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain-Barré syndrome. J Infect Dis. 1997; 176:Suppl 2. S144–S149.

7. Lin MS, Chen LY, Wang SS, Chang Y, Chen WY. Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide. Colloids Surf B Biointerfaces. 2008; 65:172–177.

8. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002; 47:434–444.

9. Jearn LH, Kim DA, Kim TY. Limitations of antinuclear antibody tests (HEp-2) are overcome with the Autoimmune Target test (IT-1) in systemic lupus erythematosus. J Rheumatol. 2009; 36:1833–1834.

10. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012; 64:2319–2327.

11. Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014; 5:3633.

12. Aspin J, Harrison R, Jehanli A, Lunt GG. Autoimmune involvement in motor neurone disease. Adv Exp Med Biol. 1987; 209:71–73.

13. Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol Res Int. 2011; 2011:497080.

14. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R. Extra-articular Manifestations in Rheumatoid Arthritis. Maedica (Buchar). 2010; 5:286–291.

15. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005; 64:297–303.

16. Huang X, Magder LS, Petri M. Predictors of incident seizure in systemic lupus erythematosus. J Rheumatol. 2016; 43:565–575.

17. Joseph V, Anil R, Aristy S. Neuropsychiatric systemic lupus erythematosus: a diagnostic conundrum. J Clin Med Res. 2016; 8:757–759.

18. Michielsens B, Walravens M, Vermylen J, Carton H. Diagnostic significance of antinuclear antibodies in neurologic patients. Acta Neurol Scand. 1991; 84:102–106.

19. Mahler M, Ngo JT, Schulte-Pelkum J, Luettich T, Fritzler MJ. Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther. 2008; 10:R131.